ARCII: A Phase II trial of the HIV protease inhibitor Nelfinavir
in combination with chemoradiation for locally advanced inoperable
pancreatic cancer

ARCII: A Phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer

Background and purpose Nelfinavir can enhance intrinsic radiosensitivity, reduce hypoxia and improve vascularity. We conducted a phase II trial combining nelfinavir with chemoradiotherapy (CRT) for locally advanced inoperable pancreatic cancer (LAPC). Materials and methods Radiotherapy (50.4 Gy/28...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Wilson, J, Fokas, E, Dutton, S, Hawkins, M, al., E
Formato:	Journal article
Publicado em:	Elsevier 2016

Registros relacionados

ARCII: Nelfinavir, a hypoxia-modifying agent, in combination with chemoradiotherapy (CRT) in locally-advanced pancreatic cancer (LAPC)–mechanism and clinical outcomes
por: Wilson, J, et al.
Publicado em: (2017)

A phase I-trial of the HIV protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer
por: Brunner, T, et al.
Publicado em: (2008)

A phase I-trial of the HIV protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer
por: Brunner, T, et al.
Publicado em: (2008)

Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer.
por: Brunner, T, et al.
Publicado em: (2008)

HIV-1 genotypes related to failure of nelfinavir as the first protease inhibitor treatment
por: Unaí Tupinambás, et al.

New insights into the in silico prediction of HIV protease resistance to nelfinavir.
por: Dinler A Antunes, et al.
Publicado em: (2014-01-01)

Alterations in the Notch4 pathway in cerebral endothelial cells by the HIV aspartyl protease inhibitor, nelfinavir
por: Chao Ying, et al.
Publicado em: (2008-02-01)

Dosimetric parameters predict toxicity in chemoradiotherapy with nelfinavir for pancreatic cancer
por: Holyoake, D, et al.
Publicado em: (2016)

Definitive chemoradiation in patients with inoperable oesophageal carcinoma.
por: Crosby, T, et al.
Publicado em: (2004)

The HIV Protease Inhibitor Nelfinavir Downregulates Akt Phosphorylation by Inhibiting Proteasomal Activity and Inducing the Unfolded Protein Response
por: Anjali K. Gupta, et al.
Publicado em: (2007-04-01)

Nelfinavir, an HIV-1 protease inhibitor, induces oxidative stress-mediated, caspase-independent apoptosis in Leishmania amastigotes.
por: Pranav Kumar, et al.
Publicado em: (2010-03-01)

Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: the phase 1/randomised phase 2 SCALOP-2 trial
por: Mukherjee, S, et al.
Publicado em: (2024)

HIV protease inhibitor nelfinavir is a potent drug candidate against echinococcosis by targeting Ddi1-like protein
por: Zhongli Liu, et al.
Publicado em: (2022-08-01)

Pneumocephalus after the Treatment of an Inoperable Superior Sulcus Tumor with Chemoradiation
por: Ashley Albert, et al.
Publicado em: (2017-01-01)

The impact of the nelfinavir resistance-conferring mutation D30N on the susceptibility of HIV-1 subtype B to other protease inhibitors
por: André FA Santos, et al.
Publicado em: (2011-03-01)

SCALOP-2: A randomised trial of induction GEMABX followed by chemoradiation (high/standard dose radiation) +/-nelfinavir for locally advanced pancreatic cancer: results of the dose-finding component
por: Mukherjee, S, et al.
Publicado em: (2018)

The radiosensitizing effects of Nelfinavir on pancreatic cancer with and without pancreatic stellate cells
por: Al-Assar, O, et al.
Publicado em: (2016)

Concurrent chemoradiation and brachytherapy alone or in combination with nelfinavir in locally advanced cervical cancer (NELCER): study protocol for a phase III trial
por: Sudeep Gupta, et al.
Publicado em: (2022-04-01)

ATR targeting by the novel inhibitor VE-822 selectively sensitizes pancreatic cancer cells and tumors to radiation and chemoradiation
por: Fokas, E, et al.
Publicado em: (2013)

The HIV protease and PI3K/Akt inhibitor nelfinavir does not improve the curative effect of fractionated irradiation in PC-3 prostate cancer in vitro and in vivo
por: Steffi Liebscher, et al.
Publicado em: (2017-02-01)

THE ROLE OF RADIOTHERAPY DELAY IN THE CHEMORADIATION TREATMENT FOR STAGE III INOPERABLE NON-SMALL CELL LUNG CANCER
por: E. P. Solov’eva, et al.
Publicado em: (2016-02-01)

Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)
por: Christoph Driessen, et al.
Publicado em: (2016-03-01)

The efficacy of nelfinavir and lopinavir/ritonavir in the treatment of HIV-infected pediatric patients
por: V. B. Denisenko,, et al.
Publicado em: (2018-12-01)

Chemoradiation of pancreatic carcinoma
por: Erdinç Nayır, et al.
Publicado em: (2016-08-01)

Nelfinavir and Non-Nucleoside Reverse Transcriptase Inhibitor-Based Salvage Regimes in Heavily Hiv Pretreated Patients
por: Jean-Guy Baril, et al.
Publicado em: (2003-01-01)

The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo
por: Camille Bono, et al.
Publicado em: (2012-07-01)

Survival and Toxicity in Patients With Unresectable or Inoperable Biliary Tract Cancers With Ablative Radiation Therapy Versus Nonablative Chemoradiation
por: Hilario Yankey, MD, MBA, et al.
Publicado em: (2024-04-01)

Combination of chemoradiation therapy with immunotherapy in the treatment of patients with inoperable stage III non-small cell lung cancer
por: N. V. Marinichenko, et al.
Publicado em: (2020-12-01)

Spectrophometric Determination of Nelfinavir Mesylate
por: K. Vanitha Prakash, et al.
Publicado em: (2006-01-01)

The association between protease inhibitors and anal cancer outcomes in veterans living with HIV treated with definitive chemoradiation: a retrospective study
por: Alison K. Yoder, et al.
Publicado em: (2021-07-01)

ACCELEREATED HYPERFRACTIONATED WITH UNEVEN CRUSHING DAILY DOSE WITH CHEMORADIATION TREATMENT OF INOPERABLE NON-SMALL CELL LUNG CANCER.
por: D. V. Gogolin, et al.
Publicado em: (2016-02-01)

Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children
por: Léon Juan, et al.
Publicado em: (2006-07-01)

Induction of Suicidal Erythrocyte Death by Nelfinavir
por: Rosi Bissinger, et al.
Publicado em: (2015-05-01)

The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma
por: Lenka Besse, et al.
Publicado em: (2023-03-01)

Nelfinavir: An Old Ally in the COVID-19 Fight?
por: Anna Gidari, et al.
Publicado em: (2022-12-01)

Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells
por: Serena Veschi, et al.
Publicado em: (2018-09-01)

Helical tomotherapy with concurrent capecitabine for the treatment of inoperable pancreatic cancer
por: Kang Young-Nam, et al.
Publicado em: (2010-06-01)

Clinical trial of oral nelfinavir before and during radiation therapy for advanced rectal cancer
por: Hill, E, et al.
Publicado em: (2016)

Downstaging of pancreatic carcinoma after neoadjuvant chemoradiation.
por: Tinkl, D, et al.
Publicado em: (2009)

Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscape
por: Camacho Ricardo J, et al.
Publicado em: (2010-08-01)